Cepheid is a listed company. Its insiders report their share dealings to SEC (Form 4). Cepheid has had no insider filing for more than a year; the last one goes back to 7 November 2016.
Looking back to 2016, when coverage begins, insiders filed no purchases and 14 sales.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2015 · cache
25 of 213 declarations
Cepheid is a company focused on developing molecular diagnostic solutions. It offers rapid and accurate tests for various medical applications.
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2015 | 538.6 m USD | -48.5 m USD | -0.67 USD | 10-K |
| Dec 2014 | 470.1 m USD | -50.1 m USD | -0.72 USD | 10-K |
| Dec 2013 | 401.3 m USD | -18.0 m USD | -0.27 USD | 10-K |
| Dec 2012 | 331.2 m USD | -20.0 m USD | -0.30 USD | 10-K |
| Dec 2011 | 277.6 m USD | 2.6 m USD | 0.04 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.